Adrenal gland tumor

Search Trials
Dovitinib in Neuroendocrine Tumors
Status:
Completed
Last Changed:
Apr 14, 2020
First Changed:
Jul 10, 2012
Disease(s):
Advanced Metastatic Paraganglioma
Intervention(s):
Dovitinib
Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Status:
Completed
Last Changed:
Feb 25, 2014
First Changed:
Apr 3, 2009
Disease(s):
Chromaffin-tissue Derived Tumors
Intervention(s):
Scintigraphy in 123I-IBZM
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Status:
Active, not recruiting
Last Changed:
Nov 5, 2021
First Changed:
Jan 27, 2017
Disease(s):
Recurrent Neuroendocrine Tumor
Intervention(s):
ONC201
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
Status:
Terminated
Last Changed:
Sep 21, 2017
First Changed:
Apr 25, 2011
Disease(s):
Extra-Adrenal Paraganglioma
Intervention(s):
Laboratory Biomarker AnalysisPazopanib Hydrochloride
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Status:
Terminated
Last Changed:
Jun 10, 2013
First Changed:
Jun 2, 2009
Disease(s):
Pheochromocytoma

Connect. Empower. Inspire.